CLONAPAM TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

CLONAZEPAM

Commercializzato da:

BAUSCH HEALTH, CANADA INC.

Codice ATC:

N03AE01

INN (Nome Internazionale):

CLONAZEPAM

Dosaggio:

0.5MG

Forma farmaceutica:

TABLET

Composizione:

CLONAZEPAM 0.5MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

Targeted (CDSA IV)

Area terapeutica:

BENZODIAZEPINES

Dettagli prodotto:

Active ingredient group (AIG) number: 0111558001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2021-03-10

Scheda tecnica

PRODUCT MONOGRAPH
CLONAPAM
®
Clonazepam Tablets, USP
0.5 mg. 1 mg, and 2 mg
ANTICONVULSANT
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 1, 2021
Laval, Quebec
H7L 4A8
Control #: 253836
_T/C_
_CLONAPAM_
_®_
_ Product Monograph Page 2 of 34_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE
REACTIONS.....................................................................................................12
DRUG INTERACTIONS
.....................................................................................................14
DOSAGE AND ADMINISTRATION
..................................................................................16
OVERDOSAGE
..................................................................................................................17
ACTION AND CLINICAL
PHARMACOLOGY..................................................................19
STORAGE AND STABILITY
.............................................................................................20
SPECIAL HANDLING INSTRUCTIONS
............................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................21
PART II: SCIENTIFIC
INFORMATION...............................................................................
22
PHARMACEUTICAL INFORMATION
..............................................................................22
CLINICAL TRIALS
...................................................